Astrazeneca Pharma India Ltd. (ASTRAZEN) Share Price Hits Fresh 52-Week Low

Astrazeneca Pharma India Ltd. traded at Rs 6,968.45, down 0.03% today, after hitting a fresh 52-week low of Rs 6,900.10. Market capitalisation stood at Rs 17,426.88 crore.

Astrazeneca Pharma India Ltd. Share Price was at Rs 6,968.45 on 01 September 2026 at 9:42 AM IST, down 0.03% from the previous close of Rs 6,970.75, after the stock touched a fresh 52-week low of Rs 6,900.10. The company’s market capitalisation stood at Rs 17,426.88 crore, placing it among the larger listed names in the Pharmaceuticals & Drugs industry.

For Astrazeneca Pharma India Ltd. Share Price Today, the verified data confirms the price event clearly: the stock opened at Rs 6,900.10, which was also the day’s low, and then moved up to an intraday high of Rs 7,024.95 before trading near flat on the day. The supplied data confirms the 52-week low event, but it does not establish a company-specific catalyst behind the move. That is why Astrazeneca Pharma India Ltd. Stock News is attracting attention more for the chart event, valuation context and peer positioning than for any verified trigger in the data provided.

For investors tracking Astrazeneca Pharma India Ltd. Share Price Live, the key numbers to monitor next are whether the stock continues to hold above the fresh yearly low, how its valuation compares with industry benchmarks, and whether its profitability profile continues to justify premium multiples. Univest highlights that this is a 52-week low event, not an all-time low call.

Astrazeneca Pharma India Ltd. Share Price Today: Price Action Analysis

Metric	Value
Current Price	Rs 6,968.45
Previous Close	Rs 6,970.75
Today's Move	Rs -2.3 (-0.03%)
Open	Rs 6,900.1
High	Rs 7,024.95
Low	Rs 6,900.1
Turnover	Rs 0.03 crore
Market Capitalisation	Rs 17,426.88 crore

Astrazeneca Pharma India Ltd. (ASTRAZEN) traded at Rs 6,968.45. versus the previous close of Rs 6,970.75, a fall of 0.03%. The stock opened at Rs 6,900.1, reached Rs 7,024.95, touched Rs 6,900.1.

Astrazeneca Pharma India Ltd. Share Price Today reflects a narrow day-on-day decline but a notable intraday test of a new one-year low, making the stock relevant in Stock Market Today and 52 Week Low Stocks discussions. The price action shows weakness at the low end of the recent range, even though the closing trade remained above the day’s trough.

The stock moved from a previous close of Rs 6,970.75 to Rs 6,968.45, a decline of Rs 2.30 or 0.03%. It opened at Rs 6,900.10, touched a high of Rs 7,024.95 and a low of Rs 6,900.10, which now stands as the fresh 52-week low. Turnover was Rs 0.03 crore. With Astrazeneca Pharma India Ltd. Market Cap at Rs 17,426.88 crore, the move was small in percentage terms but still meaningful because the stock printed a new 52-week trough.

In Astrazeneca Pharma India Ltd. Share News and Astrazeneca Pharma India Ltd. News Today searches, that distinction matters. The day’s open exactly matching the low suggests immediate pressure near the open, followed by some recovery into the session high. Available market indicators also show the stock below its 50-day moving average of Rs 7,730.23 and 200-day moving average of Rs 8,321.64, while the 14-day RSI stands at 21.48, a reading typically associated with weak momentum. That makes valuation and company financials the next logical areas to examine on Univest.

Astrazeneca Pharma India Ltd. (ASTRAZEN) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 17,426.88 crore
P/E Ratio	102.74x
P/B Ratio	19.27x
ROE	23.02%
ROCE	31.24%
EPS	Rs 67.85
Book Value Per Share	Rs 361.68
Dividend Yield	0.52%

Astrazeneca Pharma India Ltd. (ASTRAZEN) fundamental metrics show P/E 102.74x, P/B 19.27x, ROE 23.02%, ROCE 31.24%. These figures provide context only and are not a buy or sell signal.

Astrazeneca Pharma India Ltd. has a market capitalisation of Rs 17426.88 crore, which gives readers a sense of company size before judging valuation. On valuation, P/E at 102.74x, P/B at 19.27x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 23.02% and ROCE of 31.24%, helping investors compare shareholder returns and capital efficiency. Additional supplied metrics include EPS of Rs 67.85, book value per share of Rs 361.68, dividend yield of 0.52%, adding context to earnings, balance-sheet value and historical payout. Against the supplied same industry benchmark, these figures can be compared with benchmark median P/E of 30.86x, median ROE of 11.79%, median ROCE of 13.63%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Industry	Pharmaceuticals & Drugs
Benchmark Scope	same industry
Company P/E Ratio	102.74x
Benchmark Median P/E	30.86x
Benchmark Average P/E	47.7x
Benchmark P/E Range	3.87x to 667.16x
Company P/B Ratio	19.27x
Benchmark Median P/B	2.88x
Company ROE	23.02%
Benchmark Median ROE	11.79%
Company ROCE	31.24%
Benchmark Median ROCE	13.63%
Company Market Capitalisation	Rs 17,426.88 crore
Benchmark Median Market Cap	Rs 679.12 crore

Astrazeneca Pharma India Ltd. (ASTRAZEN) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.

Astrazeneca Pharma India Ltd. (ASTRAZEN) has a P/E ratio of 102.74x, which is above the benchmark median of 30.86x, a difference of +232.92%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.

Astrazeneca Pharma India Ltd. (ASTRAZEN) has a ROE of 23.02%, which is above the benchmark median of 11.79%, a difference of +95.25%. Astrazeneca Pharma India Ltd. (ASTRAZEN) has a ROCE of 31.24%, which is above the benchmark median of 13.63%, a difference of +129.2%.

Track stocks falling to yearly lows through the Univest 52-week-low screener. The peer table below provides the company-level comparison.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Suven Pharmaceuticals Ltd.	COHANCE	17,241.75	164.32	4.54	4.02	6.12
Glenmark Life Sciences Ltd.	ALIVUS	17,237.73	28.59	4.95	18.41	24.61
Shilpa Medicare Ltd.	SHILPAMED	17,685.49	62.5	6.92	9.82	11.43
Eris Lifesciences Ltd.	ERIS	18,252.81	27.93	4.45	13.81	13.59
Alembic Pharmaceuticals Ltd.	APLLTD	16,000.24	23.69	2.81	12.35	11.74

Astrazeneca Pharma India Ltd. (ASTRAZEN) has a P/E ratio of 102.74x compared with the displayed peer median of 28.59x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 23.02% compares with a peer median of 12.35% across the companies shown in the table. ROCE stood at 31.24% versus the displayed peer median of 11.74%, providing a capital-efficiency comparison. Astrazeneca Pharma India Ltd. (ASTRAZEN) has a market capitalisation of Rs 17,426.88 crore. Among the 5 peers shown, 2 have a larger market capitalisation.

Why Investors Are Watching Astrazeneca Pharma India Ltd.

• The stock touched a fresh 52-week low of Rs 6,900.10 even though the day’s decline was only 0.03%.
• Astrazeneca Pharma India Ltd. Share Price is trading below the 50-day average of Rs 7,730.23 and the 200-day average of Rs 8,321.64.
• The 14-day RSI at 21.48 places the stock in a weak-momentum zone often tracked in Oversold Stocks and Bearish Stocks screens.
• P/E of 102.74 and P/B of 19.27 remain far above industry medians despite ROE of 23.02 and ROCE of 31.24.
• The company sits in the Healthcare sector with a market cap above the same-industry average, keeping it in Stocks in News and Market Movers discussions on Univest.

About Astrazeneca Pharma India Ltd.

Astrazeneca Pharma India Ltd. is a listed Healthcare company classified under the Pharmaceuticals & Drugs industry. In market terms, it is a mid-to-large listed industry participant with a market capitalisation of Rs 17,426.88 crore. The stock trades under the symbol ASTRAZEN and is part of the Indian Stock Market universe tracked across NSE and BSE-oriented investor searches.

Based on the supplied company context, Astrazeneca Pharma India Ltd. is evaluated by investors primarily through pharmaceutical industry benchmarks such as P/E ratio, P/B ratio, ROE, ROCE, EPS, book value and dividend yield. Its current data profile shows strong return ratios and premium valuation multiples, which is why Astrazeneca Pharma India Ltd. Latest News and Astrazeneca Pharma India Ltd. Company News often draw attention when the share price reaches major technical or cyclical markers such as a one-year low. Univest tracks the stock as part of Healthcare sector and Pharmaceuticals & Drugs industry coverage.

Track Astrazeneca Pharma India Ltd. Share Price on Univest

Use Univest 52-week-low screener, Univest market blogs to review live stock data, yearly-low lists and related market analysis.

Investors using Univest can track Astrazeneca Pharma India Ltd. Share Price through live price updates, 52-week levels, market capitalisation, fundamental ratios, peer comparison metrics and sector benchmarks. Univest also helps users follow Astrazeneca Pharma India Ltd. NSE and Astrazeneca Pharma India Ltd. BSE style search intent with structured stock analysis, historical indicators, share price updates and company-level market insights, without turning those data points into recommendations.

Frequently Asked Questions

Why is Astrazeneca Pharma India Ltd. Share Price in focus today?

Ans. Astrazeneca Pharma India Ltd. Share Price is in focus because the stock touched a fresh 52-week low of Rs 6,900.10 on 01 September 2026. It later traded at Rs 6,968.45, with market capitalisation at Rs 17,426.88 crore.

What is the latest Astrazeneca Pharma India Ltd. Share Price Today?

Ans. Astrazeneca Pharma India Ltd. Share Price Today was Rs 6,968.45 at 9:42 AM IST. The stock was down 0.03% from the previous close of Rs 6,970.75 after moving between Rs 6,900.10 and Rs 7,024.95 during the session.

Did Astrazeneca Pharma India Ltd. hit a 52-week low?

Ans. Yes, the stock hit a fresh 52-week low of Rs 6,900.10 in today’s session. That level also matched the opening price and day’s low, confirming a new one-year low based on the supplied market data.

What does today’s price action show for ASTRAZEN?

Ans. Today’s price action shows early weakness followed by some recovery. ASTRAZEN opened at Rs 6,900.10, touched a high of Rs 7,024.95 and traded at Rs 6,968.45, indicating the stock moved off the fresh 52-week trough intraday.

Is Astrazeneca Pharma India Ltd. expensive compared with its industry?

Ans. On supplied valuation data, yes. The company’s P/E is 102.74 versus the same-industry median of 30.86 and average of 47.7, while its P/B is 19.27 versus the median 2.88 and average 4.27.

How profitable is Astrazeneca Pharma India Ltd. based on current ratios?

Ans. The company shows strong profitability ratios in the supplied data. ROE stands at 23.02 and ROCE at 31.24, both above the same-industry medians of 11.79 and 13.63 respectively, despite the stock’s recent weak performance.

How does Astrazeneca Pharma India Ltd. compare with peers?

Ans. Astrazeneca Pharma India Ltd. trades at a higher valuation than Glenmark Life Sciences, Eris Lifesciences and Alembic Pharmaceuticals on P/E and P/B. However, its ROE of 23.02 and ROCE of 31.24 are stronger than those peers.

What should investors track next in Astrazeneca Pharma India Ltd. Stock News?

Ans. Investors can track whether the stock holds above the fresh 52-week low of Rs 6,900.10, how Astrazeneca Pharma India Ltd. Share Price behaves relative to moving averages, and whether premium valuation continues to align with profitability metrics.